ERBB2 and neoplasm: The reduction began at the first point after treatment (FP), reached the bottom at PR, remained low at SD, and recovered to the similar levels as BL at PD, suggesting that tumor fraction in plasma ctDNA was efficiently eliminated by HER2‐targeted treatment, yet recovered along with the progression of disease.